Lucas Vieira dos Santos

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · The Lancet · 2013 · 2.2K citations · Full text

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +11

HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study

Woo Ho Kim, Lourdes Gómez Izquierdo, F Vilardell et al. · Applied immunohistochemistry & molecular morphology · 2016 · 53 citations

Esophageal Cancer, Immunology, Gastroenterology +16

REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · Journal of Clinical Oncology · 2013 · 42 citations

Esophageal Cancer, Cancer Management, Immunology +18